Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px
Organisation › Details

Genticel S.A. (Euronext Paris + Brussels: GTCL)

GENTICEL is a clinical stage biopharmaceutical company based in Paris and Toulouse, France, which develops vaccines for patients infected with Human Papillomavirus (HPV). Besides ProCervix, its other pipeline products include CyaA-based multivalent HPV vaccines with additional virus subtype coverage. *

 

Period Start 2010-03-09 renamed
Period End 2017-02-28 renamed
  Group Genkyotex (Group)
  Today Genkyotex S.A. (Euronext Paris + Brussels: GKTX)
  Predecessor BT Pharma S.A.
  Successor Genkyotex S.A. (Euronext Paris + Brussels: GKTX)
Products Industry therapeutic vaccine
  Industry 2 GTL001 (ProCervix)
Persons Person Timmerman, Benedikt (Genticel 201304 CEO + Founder)
  Person 2 Koch, Martin (Genticel 201507– interim CEO before CFO)
     
Region Region Toulouse
  Country France
  Street 515 rue Pierre et Marie Curie
  City 31682 Labège – Innopole Cedex
  Tel +33-5-6128-7060
    Address record changed: 2018-07-24
     
Basic data Employees n. a.
  Currency EUR
  Annual sales 13,104,060 (income, total (2016) 2016-12-31)
  Profit -7,240,271 (2016-12-31)
  Cash 4,663,013 (2016-12-31)
     
    * Document for �About Section�: Genticel S.A.. (4/24/13). "Press Release: Genticel Secures EUR 18.2 Million (USD 23.7 Million) in Capital Funding". Toulouse.
     
   
Record changed: 2018-10-31

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for Genkyotex (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px




» top